|Bid||7.05 x 600|
|Ask||9.70 x 200|
|Day's Range||9.45 - 9.85|
|52 Week Range||3.20 - 17.50|
|PE Ratio (TTM)||-3.41|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||18.75|
Sarepta Therapeutics Inc (NASDAQ:SRPT) Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) has outclassed expectation, leading the biotech firm to soar 20% yesterday in trading following a wow factor second-quarter earnings top-line performance. While consensus had been angling for Sarepta's second full quarter of Exondys 51 to yield $22.5 million, the firm powered through with a 114% quarterly rise to a hefty $35 million, leading management to boost full year 2017 guidance now for the second time in a year, rising from "exceeding 95 million" to an even more bullish range of $125 million to $130 million. William Blair analyst Tim Lugo highlights strong commercial trends that also led Sarepta to beat his own forecast of $20 million.
Dynavax Technologies (DVAX) needs Investors to pay close attention to the stock based on moves in the options market lately.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Dynavax Technologies Corp. Here are 5 ETFs with the largest exposure to DVAX-US. Comparing the performance and risk of Dynavax Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)